On March 18, 2015 Genmab reported that its subsidiary Genmab Holding B.V. entered into an agreement to purchase antibodies and related patents and know-how from iDD Biotech SAS (Press release, Genmab, MAR 18, 2015, View Source [SID:1234502321]). The pre-clinical stage antibodies are directed to DR5, also known as Trail Receptor 2 (TRAIL-R2), an emerging cancer target. Under the terms of the agreement, Genmab will pay iDD Biotech an upfront fee of EUR 2.5 million. Future payments range from a minimum of EUR 3.5 million to potentially EUR 101.5 million in development and sales milestones and single-digit royalties on commercialized products. This acquisition of antibody assets is synergistic with Genmab’s strategy to create a broad pipeline of differentiated therapeutic products and to leverage its deep antibody expertise to create leapfrog drugs, as it builds a sustainable business. Schedule your 30 min Free 1stOncology Demo! "We are pleased to add this exciting target and these unique DR5 antibodies to our expanding list of pre-clinical assets. This move provides Genmab with another opportunity to create potential next-generation antibody drugs which could lead to new ways of treating cancer," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!